Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 267

1.

Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease.

Bae KT, Zhou W, Shen C, Landsittel DP, Wu Z, Tao C, Chapman AB, Torres VE, Yu ASL, Mrug M, Bennett WM, Harris PC; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Clin J Am Soc Nephrol. 2019 Jun 7;14(6):823-833. doi: 10.2215/CJN.10360818. Epub 2019 May 14.

PMID:
31088850
2.

Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.

Singh S, El Rouby N, McDonough CW, Gong Y, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA.

Clin Transl Sci. 2019 Apr 29. doi: 10.1111/cts.12643. [Epub ahead of print]

PMID:
31033190
3.

Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure in African-American patients: Results from a preliminary randomized, crossover trial.

Rahbari-Oskoui FF, Abramson JL, Bruckman AM, Chapman AB, Cotsonis GA, Johnson SA, Bliwise DL.

Complement Ther Med. 2019 Apr;43:157-164. doi: 10.1016/j.ctim.2019.01.026. Epub 2019 Jan 31.

PMID:
30935524
4.

Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.

Yu ASL, Shen C, Landsittel DP, Grantham JJ, Cook LT, Torres VE, Chapman AB, Bae KT, Mrug M, Harris PC, Rahbari-Oskoui FF, Shi T, Bennett WM; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2019 May;95(5):1253-1261. doi: 10.1016/j.kint.2018.12.023. Epub 2019 Mar 4.

PMID:
30922668
5.

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.

Gansevoort RT, van Gastel MDA, Chapman AB, Blais JD, Czerwiec FS, Higashihara E, Lee J, Ouyang J, Perrone RD, Stade K, Torres VE, Devuyst O; TEMPO 3:4 Investigators.

Kidney Int. 2019 Jul;96(1):159-169. doi: 10.1016/j.kint.2018.11.044. Epub 2019 Mar 9.

PMID:
30898339
6.

The future of pharmacogenetics in the treatment of hypertension.

Cunningham PN, Chapman AB.

Pharmacogenomics. 2019 Feb;20(3):129-132. doi: 10.2217/pgs-2018-0191. Epub 2019 Feb 27. No abstract available.

7.

Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.

Solayman MH, Langaee TY, Gong Y, Shahin MH, Turner ST, Chapman AB, Gums JG, Boerwinkle E, Beitelshees AL, El-Hamamsy M, El-Wakeel L, Cooper-DeHoff RM, Badary OA, Johnson JA.

Eur J Pharm Sci. 2019 Apr 1;131:93-98. doi: 10.1016/j.ejps.2019.02.013. Epub 2019 Feb 10.

PMID:
30753892
8.

Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.

Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, Johnson JA, Turner ST, Cooper-DeHoff RM.

Am J Hypertens. 2019 Jun 11;32(7):668-675. doi: 10.1093/ajh/hpz022.

PMID:
30753254
9.

Detecting Adverse Drug Events with Rapidly Trained Classification Models.

Chapman AB, Peterson KS, Alba PR, DuVall SL, Patterson OV.

Drug Saf. 2019 Jan;42(1):147-156. doi: 10.1007/s40264-018-0763-y.

10.

Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort.

McKenzie KA, El Ters M, Torres VE, Harris PC, Chapman AB, Mrug M, Rahbari-Oskoui FF, Bae KT, Landsittel DP, Bennett WM, Yu ASL, Mahnken JD.

BMC Nephrol. 2018 Dec 27;19(1):378. doi: 10.1186/s12882-018-1182-0.

11.

Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.

Collins KS, Pratt VM, Stansberry WM, Medeiros EB, Kannegolla K, Swart M, Skaar TC, Chapman AB, Decker BS, Moorthi RN, Eadon MT.

Pharmacogenet Genomics. 2019 Jan;29(1):18-22. doi: 10.1097/FPC.0000000000000361.

PMID:
30489456
12.

Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.

Singh S, Wang Z, Shahin MH, Langaee TY, Gong Y, Turner ST, Chapman AB, Gums JG, McDonough CW, Bailey KR, Beitelshees AL, Cooper-DeHoff RM, Scherer S, Boerwinkle E, Johnson JA.

Pharmacogenet Genomics. 2018 Nov;28(11):251-255. doi: 10.1097/FPC.0000000000000353.

PMID:
30289819
13.

A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.

Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, Mustafa RA, Rastogi A, Watnick T, Yu ASL, Torres VE.

J Am Soc Nephrol. 2018 Oct;29(10):2458-2470. doi: 10.1681/ASN.2018060590. Epub 2018 Sep 18.

PMID:
30228150
14.

Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.

Sá ACC, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA.

BMC Med Genomics. 2018 Jun 20;11(1):55. doi: 10.1186/s12920-018-0370-x.

15.

Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment.

Eadon MT, Kanuri SH, Chapman AB.

Expert Rev Precis Med Drug Dev. 2018;3(1):33-47. doi: 10.1080/23808993.2018.1420419. Epub 2018 Jan 3.

16.

Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease.

Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, Kaya D, Tao C, Braun WE, Winklhofer FT, Brosnahan G, Hogan MC, Miskulin DC, Rahbari Oskoui F, Flessner MF, Perrone RD.

Kidney Int Rep. 2018 Jan 6;3(3):619-624. doi: 10.1016/j.ekir.2017.12.011. eCollection 2018 May.

17.

Detecting Evidence of Intra-abdominal Surgical Site Infections from Radiology Reports Using Natural Language Processing.

Chapman AB, Mowery DL, Swords DS, Chapman WW, Bucher BT.

AMIA Annu Symp Proc. 2018 Apr 16;2017:515-524. eCollection 2017.

18.

Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).

McDonough CW, Magvanjav O, Sá ACC, El Rouby NM, Dave C, Deitchman AN, Kawaguchi-Suzuki M, Mei W, Shen Y, Singh RSP, Solayman M, Bailey KR, Boerwinkle E, Chapman AB, Gums JG, Webb A, Scherer SE, Sadee W, Turner ST, Cooper-DeHoff RM, Gong Y, Johnson JA.

Circ Genom Precis Med. 2018 Apr;11(4):e001854. doi: 10.1161/CIRCGEN.117.001854.

19.

Hypoxia-Inducible Factor 1α (HIF-1α), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease.

Rahbari-Oskoui FF, Chapman AB.

Am J Nephrol. 2018;47(4):228-230. doi: 10.1159/000488116. Epub 2018 Mar 29. No abstract available.

20.

Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?

Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE, The Halt Pkd Investigators.

Curr Hypertens Rev. 2018;14(1):39-47. doi: 10.2174/1573402114666180322110209.

21.

Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients.

Singh S, McDonough CW, Gong Y, Alghamdi WA, Arwood MJ, Bargal SA, Dumeny L, Li WY, Mehanna M, Stockard B, Yang G, de Oliveira FA, Fredette NC, Shahin MH, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA.

J Am Heart Assoc. 2018 Mar 9;7(6). pii: e007339. doi: 10.1161/JAHA.117.007339.

22.

Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Brosnahan GM, Abebe KZ, Moore CG, Rahbari-Oskoui FF, Bae KT, Grantham JJ, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Miskulin DC, Steinman TI, Torres VE; HALT-PKD Trial Investigators.

Am J Kidney Dis. 2018 May;71(5):666-676. doi: 10.1053/j.ajkd.2017.10.023. Epub 2018 Jan 3.

23.

Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.

Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, Bae KT, Grantham JJ, Rahbari-Oskoui FF, Flessner MF, Bennett WM, Chapman AB; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP).

Kidney Int. 2018 Mar;93(3):691-699. doi: 10.1016/j.kint.2017.09.027. Epub 2017 Dec 28.

24.

Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.

Shahin MH, Gong Y, Frye RF, Rotroff DM, Beitelshees AL, Baillie RA, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA.

J Am Heart Assoc. 2017 Dec 29;7(1). pii: e006656. doi: 10.1161/JAHA.117.006656.

25.

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.

Devuyst O, Chapman AB, Shoaf SE, Czerwiec FS, Blais JD.

Kidney Int Rep. 2017 Jul 21;2(6):1132-1140. doi: 10.1016/j.ekir.2017.07.004. eCollection 2017 Nov.

26.

ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing.

Braun WE, Abebe KZ, Brosnahan G, Patterson CG, Chapman AB, Harris PC, Hogan MC, Perrone RD, Torres VE, Miskulin DC, Steinman TI, Winklhofer FT, Rahbari-Oskoui FF, Czarnecki PG, Bae KT, Grantham JJ, Flessner MF, Schrier RW.

Am J Kidney Dis. 2018 Feb;71(2):294-296. doi: 10.1053/j.ajkd.2017.09.008. Epub 2017 Dec 2. No abstract available.

27.

Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics.

Sá ACC, Webb A, Gong Y, McDonough CW, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA.

Sci Rep. 2017 Nov 22;7(1):16068. doi: 10.1038/s41598-017-16343-z.

28.

Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument.

Oberdhan D, Cole JC, Krasa HB, Cheng R, Czerwiec FS, Hays RD, Chapman AB, Perrone RD.

Am J Kidney Dis. 2018 Feb;71(2):225-235. doi: 10.1053/j.ajkd.2017.08.020. Epub 2017 Nov 14.

29.

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF.

Kidney Int Rep. 2017 Feb 21;2(3):451-460. doi: 10.1016/j.ekir.2017.02.011. eCollection 2017 May.

30.

Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease.

Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, Torres VE, Miskulin DC, Broadbent S, Marier JF.

Kidney Int Rep. 2017 Jan 16;2(3):442-450. doi: 10.1016/j.ekir.2017.01.003. eCollection 2017 May. Erratum in: Kidney Int Rep. 2018 May 22;3(4):1015.

31.

Autosomal dominant polycystic kidney disease.

Lanktree MB, Chapman AB.

CMAJ. 2017 Nov 13;189(45):E1396. doi: 10.1503/cmaj.170443. No abstract available.

32.

Protein kinase Cα deletion causes hypotension and decreased vascular contractility.

Wynne BM, McCarthy CG, Szasz T, Molina PA, Chapman AB, Webb RC, Klein JD, Hoover RS.

J Hypertens. 2018 Mar;36(3):510-519. doi: 10.1097/HJH.0000000000001596.

33.

Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M.

J Am Soc Nephrol. 2018 Feb;29(2):571-578. doi: 10.1681/ASN.2017070819. Epub 2017 Nov 8.

34.

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4.

35.

Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.

Magvanjav O, Gong Y, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshees AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Johnson JA.

J Am Heart Assoc. 2017 Nov 2;6(11). pii: e006522. doi: 10.1161/JAHA.117.006522.

36.

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.

Cornec-Le Gall E, Blais JD, Irazabal MV, Devuyst O, Gansevoort RT, Perrone RD, Chapman AB, Czerwiec FS, Ouyang J, Heyer CM, Senum SR, Le Meur Y, Torres VE, Harris PC.

Nephrol Dial Transplant. 2018 Apr 1;33(4):645-652. doi: 10.1093/ndt/gfx188.

37.

New treatment paradigms for ADPKD: moving towards precision medicine.

Lanktree MB, Chapman AB.

Nat Rev Nephrol. 2017 Dec;13(12):750-768. doi: 10.1038/nrneph.2017.127. Epub 2017 Oct 9. Review.

PMID:
28989174
38.

Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.

Mehanna M, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Johnson JA, Turner ST, Cooper-DeHoff RM.

J Clin Hypertens (Greenwich). 2017 Dec;19(12):1301-1308. doi: 10.1111/jch.13094. Epub 2017 Sep 21.

39.

A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease.

Reddy BV, Chapman AB.

Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1695-1698. doi: 10.2215/CJN.02830317. Epub 2017 Aug 7. No abstract available.

40.

Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Chonchol M, Gitomer B, Isakova T, Cai X, Salusky I, Pereira R, Abebe K, Torres V, Steinman TI, Grantham JJ, Chapman AB, Schrier RW, Wolf M.

Clin J Am Soc Nephrol. 2017 Sep 7;12(9):1461-1469. doi: 10.2215/CJN.12821216. Epub 2017 Jul 13.

41.

Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.

Kline TL, Korfiatis P, Edwards ME, Bae KT, Yu A, Chapman AB, Mrug M, Grantham JJ, Landsittel D, Bennett WM, King BF, Harris PC, Torres VE, Erickson BJ; CRISP Investigators.

Kidney Int. 2017 Nov;92(5):1206-1216. doi: 10.1016/j.kint.2017.03.026. Epub 2017 May 20.

42.

Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.

Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE; HALT PKD Investigators.

Curr Hypertens Rev. 2017;13(2):109-120. doi: 10.2174/1573402113666170427142815.

43.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators.

Nephrol Dial Transplant. 2017 Jul 1;32(7):1262. doi: 10.1093/ndt/gfx079. No abstract available.

PMID:
28444221
44.

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators.

Nephrol Dial Transplant. 2018 Mar 1;33(3):477-489. doi: 10.1093/ndt/gfx043.

45.

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.

Shoaf SE, Chapman AB, Torres VE, Ouyang J, Czerwiec FS.

J Clin Pharmacol. 2017 Jul;57(7):906-917. doi: 10.1002/jcph.880. Epub 2017 Feb 20.

46.

Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.

de Oliveira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM.

Metabolomics. 2016 Aug;12(8). pii: 129. doi: 10.1007/s11306-016-1076-8. Epub 2016 Jul 13.

47.

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.

Torres VE, Devuyst O, Chapman AB, Gansevoort RT, Perrone RD, Ouyang J, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators.

Am J Nephrol. 2017;45(3):257-266. doi: 10.1159/000456087. Epub 2017 Feb 7.

48.

Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response.

Shahin MH, Sá AC, Webb A, Gong Y, Langaee T, McDonough CW, Riva A, Beitleshees AL, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Scherer SE, Sadee W, Cooper-DeHoff RM, Johnson JA.

Circ Cardiovasc Genet. 2017 Jan;10(1). pii: e001404. doi: 10.1161/CIRCGENETICS.116.001404.

49.

Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.

Shen C, Landsittel D, Irazabal MV, Yu AS, Chapman AB, Mrug M, Grantham JJ, Bae KT, Bennett WM, Flessner MF, Torres VE; CRISP Investigators.

Am J Kidney Dis. 2017 Mar;69(3):482-484. doi: 10.1053/j.ajkd.2016.10.021. Epub 2016 Dec 24. No abstract available.

50.

Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.

Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF.

Kidney Int. 2017 Feb;91(2):493-500. doi: 10.1016/j.kint.2016.10.018. Epub 2016 Dec 16.

Supplemental Content

Loading ...
Support Center